Upstaging to invasive ductal carcinoma after mastectomy for ductal carcinoma in situ: predictive factors and role of sentinel lymph node biopsy

被引:21
|
作者
Watanabe, Yusuke [1 ]
Anan, Keisei [1 ]
Saimura, Michiyo [1 ]
Koga, Kenichiro [1 ]
Fujino, Minoru [1 ]
Mine, Mari [2 ]
Tamiya, Sadafumi [2 ]
Nishihara, Kazuyoshi [1 ]
Nakano, Toru [1 ]
Mitsuyama, Shoshu [1 ]
机构
[1] Kitakyushu Municipal Med Ctr, Dept Surg, Kokurakita Ku, 2-1-1 Bashaku, Kitakyushu, Fukuoka 8020077, Japan
[2] Kitakyushu Municipal Med Ctr, Dept Pathol, Kokurakita Ku, 2-1-1 Bashaku, Kitakyushu, Fukuoka 8020077, Japan
关键词
Breast cancer; Ductal carcinoma in situ; Sentinel lymph node biopsy; Mastectomy; STAGE BREAST-CANCER; AMERICAN-SOCIETY;
D O I
10.1007/s12282-018-0871-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background The aim of this study was to investigate preoperative factors associated with ductal carcinoma in situ (DCIS) upstaged to invasive ductal carcinoma (IDC) and sentinel lymph node (SLN) status in patients who underwent mastectomy for a preoperative diagnosis of DCIS. Methods The medical records of 220 patients who underwent mastectomy for a preoperative diagnosis of DCIS were retrospectively reviewed. Results Fifty-one (22.6%) of 226 lesions were upgraded to IDC after mastectomy. Preoperative factors associated with upstaging to IDC included patient-reported signs and symptoms, a clinically palpable mass, ultrasound findings classified as category 4 or 5, the ultrasound appearance of a mass or widely distributed non-mass abnormality (NMA), and a high Ki67 index. The prevalence of SLN macrometastasis was 0.9%. IDC was diagnosed for 10.9% of lesions of a preoperative ultrasound category of 0-3, 13.0% of those with no mass or NMA detected by ultrasonography, and 14.1% of lesions preoperatively diagnosed by methods other than core needle biopsy (CNB). Of those lesions, none was associated with SLN metastasis. Conclusions Routinely performing SLN biopsy for patients undergoing mastectomy for a preoperative diagnosis of DCIS is overtreatment, because the prevalence of SLN metastasis was low. SLN biopsy can be omitted for most patients. In particular, we suggest omitting SLN biopsy for patients who have lesions of ultrasound category 0-3, who have neither a mass nor NMA detected by ultrasound, or whose initial diagnosis was made based on a specimen obtained by methods other than CNB.
引用
收藏
页码:663 / 670
页数:8
相关论文
共 50 条
  • [1] Upstaging to invasive ductal carcinoma after mastectomy for ductal carcinoma in situ: predictive factors and role of sentinel lymph node biopsy
    Yusuke Watanabe
    Keisei Anan
    Michiyo Saimura
    Kenichiro Koga
    Minoru Fujino
    Mari Mine
    Sadafumi Tamiya
    Kazuyoshi Nishihara
    Toru Nakano
    Shoshu Mitsuyama
    Breast Cancer, 2018, 25 : 663 - 670
  • [2] The role of sentinel lymph node biopsy in ductal carcinoma in situ treated by mastectomy
    Tan, J
    McCready, DR
    Leong, WL
    ANNALS OF SURGICAL ONCOLOGY, 2006, 13 (02) : 45 - 46
  • [3] Role of sentinel lymph node biopsy in ductal carcinoma in situ and ductal carcinoma in situ with microinvasion
    Hoover, SJ
    Leitch, AM
    Euhus, DM
    Peters, GN
    ANNALS OF SURGICAL ONCOLOGY, 2002, 9 (01) : S63 - S63
  • [4] Role of Sentinel Lymph Node Biopsy in Ductal Carcinoma-in-situ Treated by Mastectomy
    Jensen C. C. Tan
    David R. McCready
    Alexandra M. Easson
    Wey L. Leong
    Annals of Surgical Oncology, 2007, 14 : 638 - 645
  • [5] Role of sentinel lymph node biopsy in ductal carcinoma-in-situ treated by mastectomy
    Tan, Jensen C. C.
    McCready, David R.
    Easson, Alexandra M.
    Leong, Wey L.
    ANNALS OF SURGICAL ONCOLOGY, 2007, 14 (02) : 638 - 645
  • [6] Could sentinel lymph node biopsy be exempted for ductal carcinoma in situ after mastectomy?
    Yang, Jiqiao
    Lv, Qing
    BREAST CANCER, 2019, 26 (02) : 260 - 260
  • [7] Could sentinel lymph node biopsy be exempted for ductal carcinoma in situ after mastectomy?
    Jiqiao Yang
    Qing Lv
    Breast Cancer, 2019, 26 : 260 - 260
  • [8] The role of sentinel lymph node biopsy in ductal carcinoma in situ
    Moran, CJ
    Kell, MR
    Kerin, MJ
    EJSO, 2005, 31 (10): : 1105 - 1111
  • [9] Is Sentinel Lymph Node Biopsy Indicated at Completion Mastectomy for Ductal Carcinoma In Situ?
    Pilewskie, Melissa
    Karsten, Maria
    Radosa, Julia
    Eaton, Anne
    King, Tari A.
    ANNALS OF SURGICAL ONCOLOGY, 2016, 23 (07) : 2229 - 2234
  • [10] Is Sentinel Lymph Node Biopsy Indicated at Completion Mastectomy for Ductal Carcinoma In Situ?
    Melissa Pilewskie
    Maria Karsten
    Julia Radosa
    Anne Eaton
    Tari A. King
    Annals of Surgical Oncology, 2016, 23 : 2229 - 2234